We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Precision Oncology Test Predicts Patient Toxicity Before Beginning Chemotherapy

By LabMedica International staff writers
Posted on 04 Jun 2025

5-fluorouracil (5FU) and capecitabine have been cornerstone chemotherapeutic agents for over four decades, effectively treating a variety of cancers. More...

However, 5FU/capecitabine can cause varying degrees of toxicity, with 30-40% of patients experiencing severe side effects such as neutropenic sepsis, hand-foot syndrome, and diarrhea. In addition, 0.5-1% of patients may suffer from life-threatening toxicity. Predicting toxicity based on physiological factors alone has proven difficult due to the complex pharmacokinetics of 5FU, which makes determining the appropriate dose challenging for individual patients. Now, a groundbreaking test can help identify patients most at risk for severe reactions to 5FU/capecitabine before treatment begins.

Oxford Cancer Biomarkers’ (OCB, Oxford, UK) proprietary ToxNav test is a precision oncology breakthrough that identifies patients most likely to experience severe toxicity from 5FU/capecitabine treatment. By detecting over 20 genotypic variants linked to adverse reactions, the test helps prevent life-threatening toxicity and reduces the associated treatment costs. After identifying a patient's genotype, ToxNav stratifies them into one of four risk categories: critical risk, high risk, standard risk, and standard risk with a high risk of hand-foot syndrome (HFS).

Unlike other biomarker tests, which typically focus on a small number of single nucleotide polymorphisms (SNPs) to assess risk, ToxNav incorporates 20 SNPs to enhance the specificity of its results. This broader genetic analysis accounts for more variants that affect DPYD gene function and disrupt the 5FU metabolic pathway, thus offering a more comprehensive understanding of toxicity risks. ToxNav has demonstrated clinically superior sensitivity and specificity compared to other tests that assess similar toxicities and is the only test with robust clinical validation from a large study.

“We developed our ToxNav test to identify cancer patients that have a high likelihood of undergoing extreme toxicity to 5FU/capecitabine treatment, which is one of the most widely used cancer drugs in the world,” said Dr. David Kerr, Founder and Director of the Board of OCB, and Professor of Cancer Medicine at Oxford University. “We have already clinically proven that ToxNav identifies patients that are susceptible to extreme toxicity.”

Related Links:
Oxford Cancer Biomarkers


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Mini Vortex Mixer
Vornado
New
Multilevel Whole Blood Calibrator Set
6PLUS1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Microbiology

view channel
Image: The U.S. FDA-cleared IntelliSep rapid host response diagnostic represents a breakthrough in sepsis care (Photo courtesy of Cytovale)

Rapid Diagnostic Test Slashes Sepsis Mortality by 39%

Sepsis remains one of the most challenging and fatal conditions in contemporary healthcare, accounting for nearly one-third of all hospital-related deaths in the United States. In emergency departments... Read more

Industry

view channel
Image: The knowledge transfer partnership will further develop technology to rapidly diagnose serious and high-risk infectious diseases (Photo courtesy of Aston University)

Aston University and BG Research Partner to Commercialize Groundbreaking Medical Diagnostic

Technology that can rapidly diagnose high-consequence infectious diseases will take a major step forward towards commercialization, thanks to a new partnership. A Knowledge Transfer Partnership (KTP)... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.